The low toxicity profile is in line with a phase I study from 2016 investigating the effects of therapeutic vaccination with short peptides from the proteins Bcl-2, Bcl-XL, and Mcl-1 in patients with relapse of multiple myeloma where no toxicity other than what was to be expected from standard treatment with bortezomib (proteasome inhibitor) were reported (36). This evidence concerns the gene BCL2 and plasma cell myeloma.